市场调查报告书
商品编码
1354295
干眼症市场规模 - 按产品、疾病类型、分销管道和预测,2023 - 2032 年Dry Eye Disease Market Size - By Product, By Disease Type, By Distribution Channel, & Forecast, 2023 - 2032 |
2023 年至 2032 年间,全球干眼症市场复合年增长率将达到 7.4%。生活方式的改变、萤幕时间的增加和环境因素导致干眼症盛行率上升。根据 NCBI 的数据,干眼症 (DED) 是一种非常常见的眼部疾病,影响全世界大量人群,不同地理区域的盛行率从 5% 到 50% 不等。此外,全球老化人口数量不断增加也支撑了市场。
干眼症市场前景受益于持续的研究和开发努力,从而产生创新的治疗方法和产品。此外,医疗保健专业人员和患者对 DED 的认识不断提高,促进了早期诊断和治疗,进一步刺激了市场成长。
整个干眼症市场根据产品、疾病类型和地区进行分类。
2023 年至 2032 年,外用皮质类固醇细分市场的复合年增长率将达到 8.4%。这些药物可有效缓解与 DED 相关的炎症,为患者提供急需的舒适感。随着人们对 DED 及其治疗方案认识的提高,加上人口老化的扩大,DED 市场对外用皮质类固醇的需求将持续上升。他们在控制干眼症方面的作用有助于增加干眼症市场的收入。
就疾病类型而言,从2023 年到2032 年,水液缺乏性干眼症的复合年增长率将达到8%。这种干眼症亚型是由于泪液产生减少而导致的,可能会导致严重不适。 ADDE 患者通常依靠专门的治疗(例如人工泪液和处方药)来有效控制病情。随着 ADDE 认识和诊断的提高,DED 市场对标靶治疗的需求持续成长。
2023 年至 2032 年,欧洲干眼症市场复合年增长率将达到 7.2%。人口老化,加上萤幕时间增加和其他环境因素,将提高干眼症的盛行率。根据欧盟统计局的数据,到 2022 年,超过五分之一(21.1%)的欧盟人口年龄在 65 岁及以上。此外,对医疗保健的日益关注以及 DED 治疗和诊断的进步推动了市场扩张。随着意识的增强,患者寻求有效的解决方案,从而增加了整个欧洲对 DED 相关产品和服务的需求。
Global Dry Eye Disease Market will witness 7.4% CAGR between 2023 and 2032. Changing lifestyles, increased screen time, and environmental factors contribute to a rising prevalence of DED. According to NCBI, dry eye disease (DED) is a highly common eye condition that impacts a substantial number of individuals worldwide, with its prevalence varying from 5% to 50% across different geographic regions. Additionally, a rising number of aging populations worldwide also supports the market.
The dry eye disease market outlook benefits from continuous research and development efforts, resulting in innovative treatments and products. Additionally, the growing awareness of DED among healthcare professionals and patients alike fosters early diagnosis and treatment, further stimulating market growth.
The overall Dry Eye Disease Market is classified based on product, disease type, and region.
The topical corticosteroids segment will witness an 8.4% CAGR from 2023 to 2032. These medications offer effective relief from inflammation associated with DED, providing much-needed comfort to patients. As awareness of DED and its management options increases, coupled with the expansion of aging populations, the demand for topical corticosteroids in the DED market will continue to rise. Their role in managing the condition contributes to the dry eye disease market revenue.
Regarding the disease type, the aqueous deficient dry eye syndrome segment will observe 8% CAGR from 2023 to 2032. This subtype of DED results from reduced tear production and can cause severe discomfort. Patients with ADDE often rely on specialized treatments, such as artificial tears and prescription medications, to manage their conditions effectively. As awareness and diagnosis of ADDE increase, the demand for targeted therapies within the DED market continues to grow.
Europe dry eye disease market will showcase 7.2% CAGR from 2023 to 2032. An aging population, in tandem with increased screen time and other environmental factors, elevates DED prevalence. According to Eurostat, in 2022, more than one-fifth (21.1 %) of the EU population was aged 65 and over. Furthermore, a growing focus on healthcare and advancements in DED treatments and diagnostics drive market expansion. As awareness grows, patients seek effective solutions, bolstering demand for DED-related products and services across Europe.